Breaking News Instant updates and real-time market news.

NEOS

Neos Therapeutics

$10.95

0.85 (8.42%)

, PFE

Pfizer

$35.38

0.08 (0.23%)

17:58
11/14/17
11/14
17:58
11/14/17
17:58

Pfizer ADHD drug supply shortage is positive for Neos, says Wells Fargo

Wells Fargo analyst David Maris says Pfizer (PFE) has sent a letter on physicians dated November 8th telling them of a supply shortage for its liquid and chewable methylphenidate ADHD products. Maris says Pfizer's product is a direct competitor of Neos' (NEOS) recently-launched Cotempla XR-ODT, adding Neos will benefit from having its primary competition in the alternative dose market facing a shortage. The analyst says Cotempla XR-ODT, launched in September, is off to a very strong start, keeping his Outperform rating with a $12 price target on Neos.

NEOS

Neos Therapeutics

$10.95

0.85 (8.42%)

PFE

Pfizer

$35.38

0.08 (0.23%)

  • 14

    Nov

  • 28

    Nov

  • 14

    Dec

NEOS Neos Therapeutics
$10.95

0.85 (8.42%)

10/26/17
COWN
10/26/17
NO CHANGE
COWN
Neos Therapeutics offer too low, $20 more reasonable, says Cowen
10/26/17
COWN
10/26/17
NO CHANGE
Target $20
COWN
Outperform
Cowen views $20 per share as more reasonable offer for Neos
Cowen analyst Tyler Van Buren calls PDL BioPharma's (PDLI) $10.25 per share offer for Neos Therapeutics (NEOS) "unreasonably low." The analyst "wholeheartedly" agrees with the Neos board's rejection of the overture. Closer to $20 per share is a "more appropriate" offer, Van Buren tells investors in a research note after Neos disclosed the approach by PDL. He believes Neos shares will eventually reach $20, which also marks his price target, without or without a takeover. The analyst keeps an Outperform rating on the shares. The stock in morning trading is 38%, or $2.74, to $10.05.
10/26/17
JMPS
10/26/17
NO CHANGE
Target $30
JMPS
Outperform
PDL buyout offer for Neos a 'starting point at best,' says JMP Securities
JMP Securities analyst Jason Butler thinks PDL BioPharma's (PDLI) $10.25 per share takeover offer undervalues Neos Therapeutics (NEOS) and believes the company seeks to bring Neos to the negotiating table by making the offer public. Butler, who expects Neos to reject PDL's offer, believes an increased bid could be attractive to shareholders. He maintains an Outperform rating and $30 price target on Neos shares.
10/26/17
WELS
10/26/17
NO CHANGE
WELS
First offer to acquire Neos Therapeutics 'good, not great,' says Wells Fargo
Wells Fargo analyst David Maris notes that PDL BioPharma (PDLI) has announced a proposal to acquire Neos (NEOS) for $10.25 per share in cash. The analyst believes this offer is in the right neighborhood, even if a bit lower value than he thinks Neos deserves considering that since the initial offer was made, Neos has received approval for Adzenys XR liquid, launched Cotempla XR-ODT, and reached a paragraph IV settlement on Adzenys XR-ODT. Maris believes that the offer will result in Neos being acquired for $10.25 or higher, but he thinks that there may be a value-enhancing opportunity should Neos' products end up in a larger company's established CNS portfolio, the benefits PDL specifically offers, considering its lack of manufacturing, regulatory, commercial or reimbursement expertise in CNS, is not immediately apparent to him.
PFE Pfizer
$35.38

0.08 (0.23%)

10/12/17
DADA
10/12/17
NO CHANGE
Target $79
DADA
Buy
Pfizer announcement creates M&A opportunity for Prestige Brands,says DA Davidson
DA Davidson analyst Linda Bolton Weiser says Pfizer's (PFE) announcement that is is reviewing strategic alternatives for its $3.4B OTC drug business could create M&A opportunity down the road for Prestige Brands (PBH). If sold, the price tag could be over $10B, clearly too big for Prestige Brands, but the buyer could later sell some or all of the small brands, the analyst contended. With Prestige Brands continuing to de-lever its balance sheet and approaching the one year anniversary in January of its last deal, Weiser believes the company could within months announce an accretive acquisition. She reiterates a Buy rating and $79 price target on Prestige Brands shares.
11/01/17
UBSW
11/01/17
NO CHANGE
Target $38
UBSW
Buy
Pfizer risk/reward remains favorable, says UBS
UBS analyst Marc Goodman said he continues to like Pfizer's risk/reward following its Q3 results. The analyst believes the company could unlock some value with potential strategic action on its consumer business and also thinks its pipeline gets minimal credit. Goodman reiterated his Buy rating and $38 price target on Pfizer shares.
11/13/17
PIPR
11/13/17
NO CHANGE
Target $54
PIPR
Overweight
Pfizer still most compelling risk/reward in global pharma, says Piper Jaffray
Piper Jaffray analyst Richard Purkis says Pfizer remains the most compelling long-run risk/reward opportunity in his global pharma coverage universe. He believes the company's key growth assets, or Ibrance, Eliquis, Xtandi, Xeljanz and Bosulif, and pipeline are being underestimated by investors. Pfizer remains one of the analyst's top 2017 picks. Purkis reiterates an Overweight rating on the shares with a $54 price target.
11/13/17
BMOC
11/13/17
NO CHANGE
BMOC
BMO says Pfizer buying Biogen makes more sense than deal for Bristol-Myers
BMO Capital analyst Alex Arfaei noted the "significant market speculation" that Pfizer (PFE) is preparing to execute a large M&A deal. While many sources, including Bloomberg, have speculated that Pfizer could target Bristol-Myers (BMY), Arfaei argues that a deal for Biogen (BIIB) would make more sense. He believes Pfizer has a significant gap in neurology, particularly in Alzheimer's, where it cannot afford to remain on the sidelines as its peers - including Biogen, Merck (MRK), AstraZeneca (AZN), and Eli Lilly (LLY) - all have pivotal trials in that area reading out in 2019-2020. Pfizer could have an opportunity to leverage near-term volatility in Biogen's MS franchise to strike a deal during the next 6-9 months before a potential interim look on aducanumab, which Arfaei views as the strongest of the next wave of Alzheimer's drugs in development, he tells investors.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.